Lauren W Roth1, Ruben Alvero2. 1. Department of Obstetrics and Gynecology, University of Colorado, Denver, Colorado 80045, USA. lauren.roth@ucdenver.edu 2. Department of Obstetrics and Gynecology, University of Colorado, Denver, Colorado 80045, USA.
Abstract
BACKGROUND: Blepharophimosis, ptosis, epicanthus inversus syndrome (BPES) type I is a rare disorder that causes a recognizable pattern of eye abnormalities and is associated with premature ovarian insufficiency. There is no data to guide the treatment of these patients when presenting with infertility. CASE: A 30-year-old, nulligravid woman with premature ovarian insufficiency associated with BPES type I presented to care secondary to a desire to conceive. Ovarian stimulation with gonadotropins was performed, and the patient conceived and delivered viable twins. CONCLUSION: It is not known whether premature ovarian insufficiency associated with BPES type I follows the same clinical course as idiopathic premature ovarian insufficiency. In patients with BPES type I who present with infertility, ovarian stimulation with gonadotropins may be a reasonable therapeutic option.
BACKGROUND:Blepharophimosis, ptosis, epicanthus inversus syndrome (BPES) type I is a rare disorder that causes a recognizable pattern of eye abnormalities and is associated with premature ovarian insufficiency. There is no data to guide the treatment of these patients when presenting with infertility. CASE: A 30-year-old, nulligravid woman with premature ovarian insufficiency associated with BPES type I presented to care secondary to a desire to conceive. Ovarian stimulation with gonadotropins was performed, and the patient conceived and delivered viable twins. CONCLUSION: It is not known whether premature ovarian insufficiency associated with BPES type I follows the same clinical course as idiopathic premature ovarian insufficiency. In patients with BPES type I who present with infertility, ovarian stimulation with gonadotropins may be a reasonable therapeutic option.
Authors: S Nuovo; M Passeri; E Di Benedetto; M Calanchini; I Meldolesi; M C Di Giacomo; D Petruzzi; M R Piemontese; L Zelante; F Sangiuolo; G Novelli; A Fabbri; F Brancati Journal: J Endocrinol Invest Date: 2015-06-23 Impact factor: 4.256